Navigation Links
Oncolytics Biotech Inc. Announces Clinical Update Conference Call
Date:11/3/2008

. Forward-looking statements, including the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
2. Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
3. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
4. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
5. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
6. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
7. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
8. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
9. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
10. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
11. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... 2008 R&D 100 Awards Now Online, ROCKAWAY, N.J., ... the 8th Annual Innovator of the Year and 43rd ... exemplify the,ideals of R&D in academia, industry, and nationally ... with ten finalists,-- five scientists and five innovators -- ...
... TOLEDO is pleased to announce that Dr. Francis Stoessel, ... Institute (SWISSI), will be the Keynote Speaker in the ... , ... Columbia, MD ...
... ALBANY, Ore., Sept. 30 Synthetech, Inc. (OTC,Bulletin ... Frederic,Farkas as Director of Manufacturing effective on October ... consulting services to Synthetech. Dr. Farkas,has over 13 ... API,manufacturing from previous positions in manufacturing and supply ...
Cached Biology Technology:2008 R&D Innovator of the Year & Scientist of the Year Finalists Announced 2Synthetech Announces New Director of Manufacturing 2
(Date:4/15/2014)... in nanoparticle form could help reduce side effects by ... years, scientists have developed nanoparticles that deliver one or ... to design particles that can carry any more than ... have devised a new way to build such nanoparticles, ... different drugs. In a paper published in the ...
(Date:4/15/2014)... University of Adelaide research into parasites of cuttlefish, ... parasites, astonishing life cycles, and shown how they ... , Researcher Dr Sarah Catalano has described 10 ... in the kidneys of cephalopods (cuttlefish, squid and ... species to be described from Australian waters. ...
(Date:4/14/2014)... hard pill to swallow, but if you,re over 24 ... terms of your cognitive motor performance, according to a ... Thompson, a psychology doctoral student, associate professor Mark Blair, ... actuarial science doctoral student, deliver the news in a ... In one of the first social science experiments to ...
Breaking Biology News(10 mins):Targeting cancer with a triple threat 2Targeting cancer with a triple threat 3Bizarre parasite may provide cuttlefish clues 2Study says we're over the hill at 24 2
... first detailed molecular images of a piece of the spike-shaped ... and initiate the first stages of infection. The structure, which ... scientists learn new details about how the virus infects cells. ... points that can be exploited by novel antiviral drugs or ...
... the Albert Einstein College of Medicine have discovered a ... may soon be able to resist the effects of ... disease-causing microbes, including Shigella and E. coli, are rapidly ... was led by Dr. John S. Blanchard, the Dan ...
... genetics of barley could lead to improved varieties of ... whisky and beer. Scientists funded in part by the ... a new programme to uncover key genes that control ... research, being carried out at the Scottish Crop Research ...
Cached Biology News:Learning how SARS spikes its quarry 2Learning how SARS spikes its quarry 3Einstein researchers identify new way that bacteria develop resistance to antibiotics 2Whisky fans can drink to crop research 2
... Combining linear motor and ballscrew ... pre-engineered Cartesian solutions that include ... management, and motors., , ... Pass through high-flex cabling for ...
UGT1A6 (D-20)...
... T Squareds patented high efficiency dynamic valve ... With the most compact, lightweight package in ... use in portable air and gas applications., ... high efficiency. , Includes DC Motor. ...
... designed for moving loads quickly and accurately. ... output while limiting overall size. The P5S-P ... ball bearings guided on two rails., ... provide energy absorption and controlled deceleration , ...
Biology Products: